Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Accumulated Expenses: 2017-2019

Historic Accumulated Expenses for Astria Therapeutics (ATXS) over the last 3 years, with Sep 2019 value amounting to $2.5 million.

  • Astria Therapeutics' Accumulated Expenses fell 9.30% to $2.5 million in Q3 2019 from the same period last year, while for Sep 2019 it was $2.5 million, marking a year-over-year decrease of 9.30%. This contributed to the annual value of $2.8 million for FY2018, which is 13.61% up from last year.
  • According to the latest figures from Q3 2019, Astria Therapeutics' Accumulated Expenses is $2.5 million, which was down 1.43% from $2.5 million recorded in Q2 2019.
  • Over the past 5 years, Astria Therapeutics' Accumulated Expenses peaked at $3.3 million during Q1 2017, and registered a low of $1.5 million during Q1 2019.
  • Its 3-year average for Accumulated Expenses is $2.6 million, with a median of $2.7 million in 2018.
  • Examining YoY changes over the last 5 years, Astria Therapeutics' Accumulated Expenses showed a top increase of 13.61% in 2018 and a maximum decrease of 34.30% in 2018.
  • Quarterly analysis of 3 years shows Astria Therapeutics' Accumulated Expenses stood at $2.4 million in 2017, then grew by 13.61% to $2.8 million in 2018, then declined by 9.30% to $2.5 million in 2019.
  • Its Accumulated Expenses stands at $2.5 million for Q3 2019, versus $2.5 million for Q2 2019 and $1.5 million for Q1 2019.